Cellectis CLLS
NASDAQ CLLS
$1.38 +0.27 (+24.32%)
At close: Nov 11, 2026 · 4:00 PM EST

Cellectis (CLLS) Liabilities from Discontinued Operations (2022 - 2023)

Updated

Cellectis (CLLS) recorded Liabilities from Discontinued Operations of $17.33 million in Q1 2023, up 16.6% from the prior quarter.

Analysis

Cellectis (CLLS) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends

At the end of FY2022, Cellectis reported Liabilities from Discontinued Operations of $14.86 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Cellectis 111.38 Mn -642.02 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 17.33 Mn
Dec 31, 2022 14.86 Mn
API Access

Cellectis Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=CLLS&period=max&api_key=YOUR_API_KEY